This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Novavax's (NVAX) Shares Surge 211% YTD: Time to Buy the Stock?
by Sundeep Ganoria
Novavax's (NVAX) shares continue to soar thanks to the recently signed partnership with Sanofi (SNY) to market its COVID-19 vaccine and develop novel COVID-19-influenza combination vaccines.
SNYNegative Net Change PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change
biotechs medical pharmaceuticals vaccines
Is AstraZeneca (AZN) a Portfolio Must-Have Pre-Q2 Earnings?
by Kinjel Shah
Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.
SNYNegative Net Change AZNNegative Net Change IONSNegative Net Change
pharmaceuticals
GSK Blenrep Combos for Multiple Myeloma Accepted for EU Review
by Zacks Equity Research
GSK announces the acceptance of its regulatory filing, seeking the approval of Blenrep combinations for the treatment of relapsed or refractory multiple myeloma, for review in the EU.
GSKPositive Net Change JNJPositive Net Change RAPTPositive Net Change ANVSPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
EMA Begins Review of Bristol Myers' (BMY) Opdivo Plus Yervoy for HCC
by Zacks Equity Research
Bristol Myers' (BMY) application seeking approval for Opdivo, in combination with Yervoy, for the indication of advanced hepatocellular carcinoma gets validation in the EU.
AZNNegative Net Change BMYPositive Net Change CORTPositive Net Change TRDANegative Net Change
biotechnology biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights Broadcom, Roche, Micron Technology and Moving iMage Technologies
by Zacks Equity Research
Broadcom, Roche, Micron Technology and Moving iMage Technologies are part of the Zacks top Analyst Blog.
RHHBYPositive Net Change MUPositive Net Change AVGOPositive Net Change MITQNegative Net Change
computers pharmaceuticals semiconductor
AbbVie (ABBV) Stock Before Q2 Earnings: To Buy or Not to Buy?
by Sundeep Ganoria
Investor focus will likely be on sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports second-quarter results.
RHHBYPositive Net Change JNJPositive Net Change ABBVPositive Net Change
biotechs earnings-preview medical pharmaceuticals
Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait?
by Ekta Bagri
While Prime Medicine (PRME) exhibits potential with its encouraging pipeline progress, the current cash position warrants caution. We advise a wait-and-watch approach at current levels.
VRTXPositive Net Change PRMENegative Net Change CRSPPositive Net Change
biotechnology biotechs gene-editing gene-therapy medical pharmaceuticals
Ionis (IONS) Completes Enrolment for Rare Disease Drug Study
by Zacks Equity Research
Ionis' (IONS) late-stage study is evaluating zilganersen in a rare neurological disorder called Alexander disease. Top-line data from this study is expected by the end of the next year.
AZNNegative Net Change NVSPositive Net Change BIIBNegative Net Change IONSNegative Net Change
biotechs medical pharmaceuticals
Should Viking (VKTX) Stock be in Your Portfolio Pre-Q2 Earnings?
by Sundeep Ganoria
Devoid of marketed drugs, investors will focus on Viking Therapeutics' (VKTX) pipeline updates when it reports second-quarter results.
NVONegative Net Change LLYNegative Net Change VKTXPositive Net Change MDGLPositive Net Change
biotechs earnings-preview medical pharmaceuticals
Pharma Stock Roundup: JNJ, NVS Q2 Earnings, RHHBY's Positive Obesity Pill Data
by Kinjel Shah
J&J (JNJ) and Novartis (NVS) beat estimates for earnings and sales. Roche's (RHHBY) oral weight loss GLP-1 therapy achieves positive results in an early-stage study.
NVSPositive Net Change RHHBYPositive Net Change JNJPositive Net Change ABBVPositive Net Change
pharmaceuticals
TEVA's Ajovy Meets Goal in Migraine Prevention Study for Kids
by Zacks Equity Research
TEVA achieves the primary efficacy endpoint with statistical significance in the phase III study of its marketed drug, Ajovy, for the prevention of episodic migraine in pediatric patients.
TEVAPositive Net Change ANIPPositive Net Change ADPTPositive Net Change RAPTPositive Net Change
biotechnology biotechs medical pharmaceuticals
AstraZeneca (AZN) Stock Rises 18% YTD: Should You Buy?
by Kinjel Shah
AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge with several candidates having blockbuster potential.
SNYNegative Net Change AZNNegative Net Change IONSNegative Net Change
pharmaceuticals
Jobless Claims Rise Again, D.R. Horton Posts Strong Quarter
by Mark Vickery
+1.867 million longer-term jobless claims is the highest single-week figure we've seen since November of 2021.
ABTNegative Net Change NFLXNegative Net Change DHIPositive Net Change
earnings home-builder medical pharmaceuticals
Novo Nordisk, Lilly Slide on Roche's Obesity Drug Study Data
by Sundeep Ganoria
Shares of obesity drugmakers Novo Nordisk (NVO) and Eli Lilly (LLY) lost market value on Wednesday after Roche (RHHBY) released positive early-stage data from a study on its obesity drug candidate.
RHHBYPositive Net Change NVONegative Net Change LLYNegative Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
by Ekta Bagri
Cassava Sciences, Inc. (SAVA) and Lexeo Therapeutics (LXEO) are in the spotlight following updates.
LXRXPositive Net Change SAVAPositive Net Change LXEONegative Net Change KYTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Company News for Jul 18, 2024
by Zacks Equity Research
Companies in The News Are: JNJ,SYF,CFG,FHN
JNJPositive Net Change FHNPositive Net Change SYFPositive Net Change CFGPositive Net Change
finance pharmaceuticals
Bayer (BAYRY) Meets Primary Goal in Nubeqa Expanded-Use Study
by Zacks Equity Research
Bayer (BAYRY) meets the primary goal in the phase III study evaluating the darolutamide/ADT combo without docetaxel in metastatic hormone-sensitive prostate cancer patients.
BAYRYNegative Net Change ANIPPositive Net Change ADPTPositive Net Change RAPTPositive Net Change
biotechnology biotechs medical pharmaceuticals
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans
by Zacks Equity Research
Ultragenyx (RARE) reaches alignment with the FDA regarding the pivotal phase III study design and endpoints for GTX-102 for Angelman syndrome, which is scheduled to be initiated later this year.
ANIPPositive Net Change RARENegative Net Change ADPTPositive Net Change RAPTPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novartis (NVS) Tops on Q2 Earnings, Ups Operating Income View
by Zacks Equity Research
Novartis' (NVS) second-quarter earnings and sales beat estimates. Based on strong momentum, the company raises its operating income outlook for 2024.
NVSPositive Net Change RHHBYPositive Net Change ARVNNegative Net Change
earnings medical pharmaceuticals
J&J (JNJ) Q2 Earnings & Sales Top, EPS View Cut on M&A Costs
by Kinjel Shah
J&J (JNJ) beats estimates for second-quarter earnings and sales. It lowers earnings expectations for 2024 due to costs related to recent acquisitions.
JNJPositive Net Change MRNAPositive Net Change HALONegative Net Change KVUEPositive Net Change
pharmaceuticals
ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ
by Zacks Equity Research
ORIC Pharmaceuticals (ORIC) teams up with Bayer and Johnson & Johnson for a phase I study on ORIC-944 in patients with metastatic prostate cancer. Its shares rise on the news.
JNJPositive Net Change BAYRYNegative Net Change ORICPositive Net Change TRDANegative Net Change
biotechnology biotechs medical pharmaceuticals
Housing Starts Increased More Than Expected
by Zacks Equity Research
Housing Starts Increased More Than Expected
JNJPositive Net Change UALPositive Net Change AAPositive Net Change
airlines medical pharmaceuticals
FDA Accepts Lexicon's (LXRX) NDA for Type I Diabetes Drug
by Zacks Equity Research
The FDA accepts Lexicon's (LXRX) resubmission seeking approval for sotagliflozin to treat adults with type 1 diabetes. A final decision is expected by Dec 20.
AZNNegative Net Change LLYNegative Net Change LXRXPositive Net Change
biotechs medical pharmaceuticals
Pre-Markets Book Profits; Housing Starts, J&J Q2 Up
by Mark Vickery
Pre-market futures are down at this hour, but not apparently as a result of any new reports ahead of the bell.
JNJPositive Net Change UALPositive Net Change AAPositive Net Change
consumer-staples earnings home-builder pharmaceuticals
Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why
by Zacks Equity Research
Arcutis (ARQT) rises 30.9% in a month after the label expansion of its marketed product, Zoryve cream 0.15%, for the AD indication in adult and pediatric patients aged six years and older.
ANIPPositive Net Change ADPTPositive Net Change RAPTPositive Net Change ARQTPositive Net Change
biotechnology biotechs medical pharmaceuticals